Montelukast

Generic Name
Montelukast
Brand Names
Singulair
Drug Type
Small Molecule
Chemical Formula
C35H36ClNO3S
CAS Number
158966-92-8
Unique Ingredient Identifier
MHM278SD3E
Background

Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...

Indication

Montelukast is indicated for:
...

Associated Conditions
Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
Associated Therapies
-
Clinical Trials
Related News

Dose Finding Study for QAW039 in Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: QAW039
Drug: Montelukast
Drug: Placebo
First Posted Date
2011-09-21
Last Posted Date
2020-12-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1043
Registration Number
NCT01437735
Locations
🇬🇧

Novartis Investigative Site, Glasgow - Scotland, United Kingdom

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

First Posted Date
2011-09-12
Last Posted Date
2021-10-20
Lead Sponsor
Maisonneuve-Rosemont Hospital
Target Recruit Count
12
Registration Number
NCT01432080
Locations
🇨🇦

Maisonneuve-Rosemont Hospital (Hôpital Maisonneuve-Rosemont), Montreal, Quebec, Canada

Safety and Efficacy of YHD001 in Asthma

First Posted Date
2011-08-26
Last Posted Date
2014-07-10
Lead Sponsor
Yuhan Corporation
Target Recruit Count
56
Registration Number
NCT01424124
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma

First Posted Date
2011-07-27
Last Posted Date
2014-07-14
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Target Recruit Count
99
Registration Number
NCT01404013
Locations
🇨🇳

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China

Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing

Not Applicable
Completed
Conditions
Bronchiolitis
Wheezing
Cough
Interventions
Drug: Montelukast
First Posted Date
2011-06-09
Last Posted Date
2011-06-14
Lead Sponsor
Hormozgan University of Medical Sciences
Target Recruit Count
146
Registration Number
NCT01370187
Locations
🇮🇷

Hormozgan University of Medical Sciences (HUMS), Bandar Abbas, Hormozgan, Iran, Islamic Republic of

The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics

Not Applicable
Completed
Conditions
Asthma
Inflammation
Obesity
Interventions
Drug: Placebo
Drug: Montelukast
First Posted Date
2011-04-06
Last Posted Date
2016-04-07
Lead Sponsor
Northwell Health
Target Recruit Count
26
Registration Number
NCT01329939
Locations
🇺🇸

North Shore-Long Island Jewish Health System, Division of Allergy/Immunology, Great Neck, New York, United States

Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population

First Posted Date
2011-04-05
Last Posted Date
2017-07-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
9906
Registration Number
NCT01328964

Montelukast for Persistent Cough in Young People and Adults

First Posted Date
2011-01-19
Last Posted Date
2012-10-10
Lead Sponsor
University of Oxford
Target Recruit Count
276
Registration Number
NCT01279668
Locations
🇬🇧

University of Oxford, Oxford, Oxfordshire, United Kingdom

A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: JNJ 40929837
Drug: Placebo
Drug: Montelukast
First Posted Date
2010-11-16
Last Posted Date
2015-12-21
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
22
Registration Number
NCT01241422

Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3

Not Applicable
Terminated
Conditions
Asthmatic Patients
Interventions
Drug: Montelukast
Drug: long acting beta2 mimetic
First Posted Date
2010-10-20
Last Posted Date
2014-10-23
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
1
Registration Number
NCT01224964
Locations
🇧🇪

University Hospital of Leuven, Leuven, Vlaams-Brabant, Belgium

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy